Ask us a question 520 547-3440 info@c-path.org

Subscribe

Home
About
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS

BmDR

Biomarker Data Repository

MSOAC

Multiple Sclerosis Outcome Assessments Consortium

CPAD

Critical Path for Alzheimer’s Disease

PRO Consortium

Patient-Reported Outcome Consortium

CPP

Critical Path for Parkinson’s

PKDOC

Polycystic Kidney Disease Outcomes Consortium

CP-RND

Critical Path for Rare Neurodegenerative Diseases

PredicTox KE

PredicTox Knowledge Environment

CP-SCD

Critical Path for Sickle Cell Disease

PSTC

Predictive Safety Testing Consortium

CPTA

Critical Path to Therapeutics for the Ataxias

QuantMed

Quantitative Medicine Program

CDRC

CURE Drug Repurposing Collaboratory

RDCA-DAP

Rare Disease Cures Accelerator-Data and Analytics Platform

DCC

Data Collaboration Center

RD-COA Consortium

Rare Disease Clinical Outcome Assessment Consortium

D-RSC

Duchenne Regulatory Science Consortium

TB-PACTS

TB-Platform for Aggregation of Clinical TB Studies

eCOA Consortium

Electronic Clinical Outcome Assessment Consortium

TTC

Transplant Therapeutics Consortium

FA-ICD

Friedreich’s Ataxia Integrated Clinical Database

TOMI-T1D

Trial Outcome Markers Initiative in T1D Consortium

HD-RSC

Huntington’s Disease Regulatory Science Consortium

TRxA

Translational Therapeutics Accelerator

INC

International Neonatal Consortium

T1D

Type 1 Diabetes Consortium

Completed Consortia

CFAST

Coalition for Accelerating Standards & Therapies

PTC

Pediatric Trials Consortium

CPTR

Critical Path to TB Drug Regimens
C-Path in Europe
Tools & Platforms
Impact
News & Events
- Events
- News
- Videos
- Publications
- Presentations
- Press Releases
Donate

News

Home>News & Events>Data Contributors>Eisai Europe

News

May 9, 2013 PRINT PDF

Eisai Europe

C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform
C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals
Webinar: TRxA 2023 Funding Opportunities
Using Real World Data from CURE ID to Identify Drug Repurposing Opportunities in Mycology: Impact of Climate Change
Polycystic Kidney Disease Drug Development: A Conference Report

Annual Reports
Contact
Donate
Employment
Explore C-Path
FAQs
FDA Acknowledgement
Policies
GDPR SCCs
Privacy Policy
Terms of Use

C-Path Main Office 1840 E River Rd, Suite 100
Tucson, AZ. 85718
Tel: 520-547-3440
Fax: 520-547-3456 C-Path Global Ltd. 33 Sir John Rogerson’s
Dublin 2, Ireland

Ask us a question Tel: 520-547¬3440
Email: info@c-path.org Subscribe

x

Contact Us

Name

Email

Phone

Message

News

News

Eisai Europe

Related Posts